Jutarat Thewsoongnoen

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Anna Turkova, Hylke Waalewijn, Man K. Chan et al. · The Lancet HIV · 2022 · 23 citations · Full text

Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial

Alexandra Compagnucci, Man K. Chan, Yacine Saïdi et al. · EClinicalMedicine · 2023 · 14 citations · Full text

The activation of B cells enhances DC-SIGN expression and promotes susceptibility of B cells to HPAI H5N1 infection

Prasit Na-Ek, Jutarat Thewsoongnoen, Maytawan Thanunchai et al. · Biochemical and Biophysical Research Communications · 2017 · 13 citations

Autoimmune Disease, Pathogenesis, Immunology +12

The presence of monocytes enhances the susceptibility of B cells to highly pathogenic avian influenza (HPAI) H5N1 virus possibly through the increased expression of α2,3 SA receptor

Patharapan Lersritwimanmaen, Prasit Na-Ek, Maytawan Thanunchai et al. · Biochemical and Biophysical Research Communications · 2015 · 10 citations

Host Response, α2,3 Sa Receptor, Innate Immune System +12